17-7-2　ⓔ文献

  1. More GS, Thomas AB, et al: Nitrogen mustards as alkylating agents: a review on chemistry, mechanism of action and current USFDA Status of drugs. Anticancer Agents Med Chem, 2019; 19: 1080–1102.

  2. Tew KD, Colvin OM, et al: Alkylating agents, Cancer Chemotherapy and biotherapy, 3rd ed (Chabner BA, Longo DL, ed), Lippincott–Raven Publishers, 2001; 373–414.

  3. Al–Juhaishi T, Khurana A, et al: Therapy–related myeloid neoplasms in lymphoma survivors: Reducing risks. Best Pract Res Clin Haematol, 2019; 32: 47–53.

  4. Cheson BD, Brugger W, et al: Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel–an update. Leuk Lymphoma, 2016; 57: 766–782.

  5. Goldman ID, Chattopadhyay S, et al: The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Investig Drugs, 2010; 11: 1409–1423.

  6. Plunkett W: Saturation of 1–beta–D-arabinofuranosylcytosine 5'–triphosphate accumulation in leukemia cells during high–dose 1–beta–D–arabinofuranosylcytosine therapy. Cancer Res, 1987; 47: 3005–3011.

  7. Yamauchi T, Ueda T, et al: A new sensitive method for determination of intracellular 1–beta–D–arabinofuranosylcytosine 5'–triphosphate content in human materials in vivo. Cancer Res, 1996; 56: 1800–1804.

  8. Fenaux P, Mufti GJ, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher–risk myelodysplastic syndromes: a randomised, open–label, phase III study. Lancet Oncol, 2009; 10: 223–232.

  9. Gandhi V, Estey E, et al: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol, 1993; 11: 116–124.

  10. Yamauchi T, Nowak BJ, et al: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4–hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res, 2001; 7: 3580–3589.

  11. Dalton WS, Grogan TM, et al: The role of P–glycoprotein in drug–resistant hematologic malignancies. Cancer Treat Res, 1991; 57: 187–208.